Cyclerion Therapeutics (CYCN) Cash & Equivalents (2019 - 2025)

Cyclerion Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $3.2 million for Q4 2025.

• In Q4 2025, Cash & Equivalents changed 0.25% year-over-year to $3.2 million; the TTM figure through Dec 2025 stood at $3.2 million (changed 0.25% YoY), while the FY2025 annual figure was $3.2 million, changed 0.25% from the prior year.
• Cash & Equivalents was $3.2 million for Q4 2025 at Cyclerion Therapeutics, down from $4.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $70.4 million in Q2 2021 to a low of $2.9 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $19.7 million across 5 years, with a median of $7.4 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents tumbled 82.57% in 2023, then soared 59.05% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $54.0 million in 2021, then tumbled by 75.2% to $13.4 million in 2022, then plunged by 43.42% to $7.6 million in 2023, then tumbled by 57.31% to $3.2 million in 2024, then advanced by 0.25% to $3.2 million in 2025.
• The last three Cash & Equivalents figures came in at $3.2 million (Q4 2025), $4.6 million (Q3 2025), and $3.0 million (Q2 2025), per Business Quant data.